Immedica Completes Major Rare Disease Acquisition, Expands Global Endocrinology Footprint

Immedica Pharma finalized its $65 million acquisition of Neurocrine Group Limited. This strategic move adds Alkindi and Efmody, critical hydrocortisone therapies for rare adrenal conditions, to Immedica's portfolio. The deal establishes rare endocrinology as a new therapeutic area, bolstering Immedica's market position across Europe and beyond. It promises enhanced patient access to essential treatments for adrenal insufficiency and congenital adrenal hyperplasia. This expansion fuels Immedica’s long-term growth and commitment to specialty care.

Immedica Pharma AB has officially completed its acquisition of Neurocrine Group Limited. The $65 million all-cash transaction marks a significant expansion for the Stockholm-based pharmaceutical company. Immedica now owns the global rights to Alkindi® and most global rights to Efmody®. These products address critical unmet medical needs within rare endocrinology. The deal, first announced on January 8, 2026, closed swiftly, solidifying Immedica's strategic vision.

The acquisition fundamentally strengthens Immedica's rare disease platform. It introduces rare endocrinology as a new, vital therapeutic area. This move aligns with Immedica’s focus on specialty care. The added portfolio brings two established, commercially available orphan products. These therapies hold a strong and growing market position. They target adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH), both severe conditions.

Alkindi® (hydrocortisone oral granules) is a patented, immediate-release formulation. It offers precise, age-appropriate dosing for children. Young patients suffering from adrenal insufficiency, including AI related to CAH, benefit greatly. Efmody® (hydrocortisone modified-release hard capsules) provides a physiological cortisol profile. Its unique twice-daily regimen mimics the body's natural circadian rhythm. This benefits adolescents and adults with CAH, also reducing excess androgens. Both drugs are hydrocortisone-based, a cornerstone of treatment for these chronic conditions.

Adrenal insufficiency (AI) is a rare endocrine disorder. The adrenal glands fail to produce enough cortisol. Cortisol is a vital hormone for metabolic function and stress response. Congenital adrenal hyperplasia (CAH) is a genetic form of primary AI. It stems from enzyme defects in cortisol synthesis. These conditions affect approximately 41 per 100,000 people. CAH accounts for about 7 per 100,000. Common symptoms include fatigue, low blood pressure, nausea, and reduced stress tolerance. Lifelong glucocorticoid replacement therapy, typically with hydrocortisone, is essential. It prevents life-threatening adrenal crises.

Immedica gains immediate and sustainable revenue contributions. Alkindi and Efmody are established and growing products. NGL, now part of Immedica, previously marketed these directly in Europe. Commercial partnerships extended their reach globally. This acquisition builds on Immedica’s strong presence across Europe and the Middle East. It facilitates continued expansion into additional geographies. This strategy supports long-term value creation through focused portfolio growth.

The acquisition was advised by top legal and intellectual property firms. Gibson, Dunn & Crutcher LLP provided legal counsel. Fuchs Patentanwälte Partnerschaft mbB handled intellectual property matters. Their expertise ensured a smooth transition.

Immedica, headquartered in Stockholm, Sweden, specializes in rare diseases. Its capabilities span marketing, sales, compliance, and regulatory affairs. It boasts a global distribution network serving over 50 countries. The company is dedicated to addressing large unmet medical needs. Its existing therapeutic areas include rare metabolic, rare hematology & oncology, and rare neurology. This deal adds a crucial new pillar: rare endocrinology. Immedica, founded in 2018, employs approximately 180 people. It is backed by investment firms KKR and Impilo, signifying strong financial support.

This strategic move reinforces Immedica’s commitment to patient care. It expands access to crucial hydrocortisone therapies worldwide. For patients with AI and CAH, continuity of care is paramount. Immedica pledges to ensure this. The acquired portfolio brings attractive, growing, and durable revenues. This strengthens Immedica’s platform for sustained long-term growth in the competitive rare disease market. The integration of NGL’s assets and expertise is expected to yield substantial synergies. This further solidifies Immedica's position as a leader in rare disease pharmaceutical commercialization.